Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today highlighted ...

SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on ...

First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally ...

First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally ...

Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

Press Release: Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem First characterization of its novel conjugation technology for creating ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

New types of antibody drugs, such as antibody-drug conjugates, antibody fragments, and multi-specific antibodies, will boost ...

Akeso Biopharma, is pleased to announce that Dr. Michelle Xia , the company's founder, chairwoman, president, and CEO, will ...

Celltrion Inc. posted preclinical study results of two new antibody-drug conjugate (ADC) candidates – CT-P70 and CT-P71 – at ...